Results 21 to 30 of about 301,139 (266)

Neonatal Fc receptor and IgG-based therapeutics [PDF]

open access: yesmAbs, 2011
The majority of potent new biologics today are IgG-based molecules that have demonstrated tissue-targeting specificity with favorable clinical response. Several factors determine the efficacy of these products, including target specificity, serum half-life and effector functions via complement-dependent cytotoxicity, antibody-dependent cell-mediated ...
Timothy T, Kuo, Victoria G, Aveson
openaire   +2 more sources

Immunoglobulin G1 binding with various molecular receptors: A new paradigm of IgG1 as a potential adjuvant

open access: yesJournal of Acute Disease, 2019
Objective: To explore the possible IgG1 binding receptors by protein-protein docking experiments. Methods: The protein-protein cognate interactions such as IgG with Fc Receptors (FcRs) potentiate signaling cascades to ameliorate antigen uptake ...
Shweta Saxena   +3 more
doaj   +1 more source

Increased levels of a pro-inflammatory IgG receptor in the midbrain of people with schizophrenia

open access: yesJournal of Neuroinflammation, 2022
Background There is growing evidence that neuroinflammation may contribute to schizophrenia neuropathology. Elevated pro-inflammatory cytokines are evident in the midbrain from schizophrenia subjects, findings that are driven by a subgroup of patients ...
A. Petty   +8 more
doaj   +1 more source

Pentraxins and Fc Receptor-Mediated Immune Responses

open access: yesFrontiers in Immunology, 2018
C-reactive protein (CRP) is a member of the pentraxin family of proteins. These proteins are highly conserved over the course of evolution being present as far back as 250 million years ago.
Jinghua Lu   +4 more
doaj   +1 more source

Autoantibodies against muscarinic receptors in breast cancer: their role in tumor angiogenesis. [PDF]

open access: yesPLoS ONE, 2013
The presence of autoantibodies in cancer has become relevant in recent years. We demonstrated that autoantibodies purified from the sera of breast cancer patients activate muscarinic acetylcholine receptors in tumor cells.
María Gabriela Lombardi   +7 more
doaj   +1 more source

Cellular surface plasmon resonance-based detection of anti-HPA-1a antibody glycosylation in fetal and neonatal alloimmune thrombocytopenia

open access: yesFrontiers in Immunology, 2023
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can occur due to maternal IgG antibodies targeting platelet antigens, causing life-threatening bleeding in the neonate.
Zoltán Szittner   +26 more
doaj   +1 more source

Natural Killer Cells in Paediatric Soft Tissue Sarcomas: A Systematic Review

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Paediatric soft tissue sarcomas (pSTS) are a rare and heterogeneous group of malignant tumours arising in tissues of mesenchymal origin. The role of natural killer (NK) cells in pSTS remains poorly understood, with evidence fragmented across small preclinical studies and early‐phase clinical trials.
Raya Dean   +7 more
wiley   +1 more source

Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III. [PDF]

open access: yesPLoS Pathogens, 2014
Human cytomegalovirus (HCMV) establishes lifelong infection with recurrent episodes of virus production and shedding despite the presence of adaptive immunological memory responses including HCMV immune immunoglobulin G (IgG).
Eugenia Corrales-Aguilar   +11 more
doaj   +1 more source

Characterization of the IgG-Fc receptor on human platelets [PDF]

open access: yesBlood, 1982
To determine quantitatively the number and avidity of receptors for the Fc portion of IgG on human platelets, we have measured the binding to platelets of human monomeric monoclonal IgG, and of small covalently crosslinked polymers of IgG1 labeled with 125I. The binding of labeled IgG1 monomers to platelets is too weak to permit quantitation.
S P, Karas, W F, Rosse, R J, Kurlander
openaire   +3 more sources

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy